Canabo Medical Inc. (TSX VENTURE:CMM) (“Canabo” or the “Company”) today announces its intention to complete a 7,500 patient observational study in 2017. The study will be led by Andrew Davis, Ph.D., of Acadia University, and will focus on correlations within the patient database in three specific areas;
relation of opioid use following cannabinoid therapies by condition and patient category relation of benzodiazepines use following cannabinoid therapies by condition and patient category, and change in quality of life measurements following cannabinoid therapies by condition and patient category.
The study will complete participant enrollment in 2017, is expected to publish initial results in late 2017, and complete study findings in 2018. Canabo is also pleased to announce it has entered into an agreement with Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) (“Aphria”) for the private placement of 6,000,000 common shares (the “Shares”) at a price of $1.40 per Share, to raise gross...
See Article on Marijuana Stocks